Table 3.
Outcomes of patients with AIP.
| Overall |
% | Type 1 AIP§ |
% | Type 2 AIP§ |
% | p-value | NOS-AIP§ |
% | |
|---|---|---|---|---|---|---|---|---|---|
| (n = 173) | (n = 106) | (n = 48) | (n = 19) | ||||||
| Diabetes | |||||||||
| Occurred before the beginning of AIP | 19 | 11 | 14 | 13.2 | 3 | 6.3 | 0.2 | 2 | 10.5 |
| Occurred simultaneously with AIP | 19 | 11 | 14 | 13.2 | 5 | 10.4 | 0.63 | 0 | 0 |
| Occurred during follow-up | 16 | 9.2 | 12 | 11.3 | 4 | 8.3 | 0.57 | 0 | 0 |
| Atrophy at imaging | 45 | 26 | 27 | 25.5 | 15 | 31.3 | 0.46 | 3 | 15.8 |
| Clinical evidence of steatorrhoea | 24 | 13.9 | 13 | 12.3 | 11 | 22.9 | 0.09 | 0 | 0 |
| Faecal elastase value (on 54 patients) | |||||||||
| >100 and <200 mcg/g | 9 (on 54) | 16.7 | 2 (on 106) | 1.9 | 6 (on 48) | 12.5 | 0.09 | 1 (on 19) | 5.3 |
| <100 mcg/g | 23 (on 54) | 42.6 | 17 (on 106) | 16 | 5 (on 48) | 10.4 | 0.36 | 1 (on 19) | 5.3 |
| Pancreatic calcifications | 17 | 9.8 | 9 | 8.5 | 5 | 10.4 | 0.7 | 3 | 15.8 |
§AIP: Autoimmune pancreatitis; °NOS: Not Otherwise Specified.